Johnson & Johnson Chief Executive Officer Alex Gorsky declined to appear at a U.S. congressional hearing on the safety of the company’s Baby Powder and other talc-based cosmetics.
The U.S. Supreme Court turned away a novel case by Arizona seeking to recover billions of dollars that the state has said that members of the Sackler family – owners of Purdue Pharma LP – funneled out of the OxyContin maker before the company filed for bankruptcy in September 2019.
Johnson & Johnson said recent tests showed that Johnson’s Baby Powder was free of asbestos, after FDA investigations reported trace amounts of the material in the product earlier in 2019.
Johnson & Johnson said recent tests showed that Johnson’s Baby Powder was free of asbestos, after FDA investigations reported trace amounts of the material in the product earlier in 2019.
Seattle Genetics is looking for a quicker path to resolution with Daiichi Sankyo over antibody drug conjugate technology that both companies claim ownership of.
Powder Keg: FDA bowed to industry for decades as alarms were sounded over talc
Asbestos, Business, Cancer Prevention Coalition, Consumers, Cosmetics, Department Of Justice, FDA, FDA/Regulatory, Food Safety and Applied Nutrition (JIFSAN), Health Concerns, Lawsuits, Minerals, Talc, Talc-Based Products, U.S. Securities and Exchange Commission (SEC), World Health OrganizationOver the past 50 years, the FDA has relied upon – and often deferred to – industry even as outside experts and consumers repeatedly raised serious health concerns about talc powders and cosmetics, a Reuters investigation found.
The state of California sued Juul Labs Inc., alleging the e-cigarette maker engaged in a “systematic” and “wildly successful” campaign to attract teenagers to the San Francisco company’s nicotine devices.
Daiichi Sankyo is taking Seattle Genetics to court over the technology the two companies used to develop antibody-drug conjugates (ADCs) during a partnership that spanned seven years.
Mallinckrodt receives SEC subpoena over Acthar gel lawsuit
Addictions, Business, Centers for Medicare and Medicaid Services (CMS), Department of Health and Human Services (HHS), Gels, Generics, Infantile Spasms, Lawsuits, Manufacturing, Multiple Sclerosis, Opioid Litigation, Opioids, Shares, U.S. Securities and Exchange Commission (SEC)Mallinckrodt Plc received a subpoena from the U.S. Securities and Exchange Commission for documents related to the drugmaker’s lawsuit against the U.S. Department of Health and Human Services (HHS).
Allergan will pay $750 million to settle a class action lawsuit from a group of direct purchasers of the Alzheimer’s disease therapy Namenda in a resolution to the litigation that was set to face trial.
